US Patent

US12545647 — Crystalline salts of a plasma kallikrein inhibitor

Composition of Matter · Assigned to Biocryst Pharmaceuticals Inc · Expires 2039-11-01 · 13y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline salts of a plasma kallikrein inhibitor, methods to prepare them, and related pharmaceutical preparations.

USPTO Abstract

Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.

Drugs covered by this patent

Patent Metadata

Patent number: US12545647
Jurisdiction: US
Classification: Composition of Matter
Expires: 2039-11-01
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Biocryst Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.